Chronic Lymphocytic Leukemia Quiz

Quiz

Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia

06/27/2022

True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.

True or False: Compared with...

06/27/2022

Journal of Clinical Pathways

Quiz

Quiz: First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL

04/18/2022

True or False: Patients with CLL or SLL who discontinued venetoclax as first-line therapy had a greater disease burden and risk of tumor lysis syndrome when compared with patients who completed at least 12 cycles of treatment with venetoclax.

True or False: Patients with CLL...

04/18/2022

Journal of Clinical Pathways

Quiz

Quiz: The Impact of Atrial Fibrillation on CLL

03/24/2022

True or False: Patients with CLL with atrial fibrillation may be at a significantly decreased risk of all-cause mortality, cardiac-related mortality, and stroke.

True or False: Patients with CLL...

03/24/2022

Journal of Clinical Pathways

Quiz

Quiz: Risk of Infusion Reactions in Patients With CLL Receiving Obinutuzumab

02/22/2022

True or False: Using chlorambucil before obinutuzumab and using a slow initial obinutuzumab infusion rate may reduce risk of infusion reactions in patients with CLL.

True or False: Using...

02/22/2022

Journal of Clinical Pathways

Quiz

Quiz: Ibrutinib Safety for Relapsed/Refractory CLL

01/13/2022

True or False: Single-agent ibrutinib is safe and effective for relapsed/refractory CLL in routine practice.

True or False: Single-agent...

01/13/2022

Journal of Clinical Pathways

Quiz

Quiz: Cost-Effectiveness of Venetoclax Plus Obinutuzumab for CLL

11/22/2021

True or False: Fixed duration venetoclax plus obinutuzumab for 12 months is a cost-effective first-line treatment option for unfit patients with chronic lymphocytic leukemia.

True or False: Fixed duration...

11/22/2021

Journal of Clinical Pathways

Quiz

Quiz: Treatment Discontinuation Among Patients With CLL

10/19/2021

True or False: The most common reason for novel oral drug discontinuation among patients with CLL in the real-world setting is due to adverse events.

True or False: The most common...

10/19/2021

Journal of Clinical Pathways

Quiz

Quiz: Cardiovascular Risks for Patients With CLL Receiving Ibrutinib

10/08/2021

True or False: Ibrutinib is associated with higher risk of atrial fibrillation, bleeding, and heart failure, but not acute myocardial infarction or stroke among patients with chronic lymphocytic leukemia.

True or False: Ibrutinib is...

10/08/2021

Journal of Clinical Pathways

Quiz

Quiz: Bendamustine Costs for Patients With CLL and NHL

09/10/2021

True or False: Small-volume, short-duration infusions of bendamustine for patients with CLL and NHL are associated with low acquisition costs and low administration labor costs compared to large-volume, long-duration infusions.

True or False: Small-volume,...

09/10/2021

Journal of Clinical Pathways

Quiz

Quiz: Rituximab Cost for CLL and NHL

07/23/2021

True or False: Intravenous rituximab-abbs yields significant annual cost savings compared to subcutaneous rituximab for patients with NHL and CLL.

True or False: Intravenous...

07/23/2021

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Chronic Lymphocytic Leukemia Quiz

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products